Entera Bio CEO to Present at Leerink Partners Healthcare Conference
Event summary
- Entera Bio CEO Miranda Toledano to participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2026 on March 11, 2026.
- Event will be held in person at W South Beach, Miami, Florida, with a live webcast and 365-day replay available.
- Entera Bio focuses on oral peptide and protein replacement therapies, with EB613 (oral PTH(1-34)) as its most advanced product candidate.
- Company collaborates with OPKO Health on oral GLP-2 peptide for malabsorption conditions.
The big picture
Entera Bio's participation in the Leerink Partners conference underscores its strategic focus on transforming peptide and protein replacement therapies into oral formulations. The company's pipeline, particularly EB613 for osteoporosis, positions it at the forefront of a shift towards more patient-friendly treatments. Collaborations like the one with OPKO Health further solidify its standing in the biotech sector, where oral therapies are increasingly sought after for their convenience and potential to improve compliance.
What we're watching
- Clinical Progress
- How Entera Bio's Phase 2 study results for EB613 will influence investor confidence and potential partnerships.
- Market Positioning
- Whether Entera Bio can sustain its lead in oral peptide therapies amid increasing competition.
- Regulatory Pathway
- The pace at which Entera Bio advances its pipeline through regulatory approvals.
Related topics